Abstract:The dysregulation of cell cycle control is a hallmark of cancer and targeting cyclin-dependent kinases (CDKs) has emerged as a promising strategy in advanced breast cancer. The G1 CDKs are the recipients of the oncogenic signals that travel from the cell surface to the nucleus, and as such, selective inhibition of CDK2, CDK4 and CDK6 has been a goal in oncology for several decades. We present a novel approach involving modulation of the CDK interacting protein p27Kip1, to simultaneously inhibit CDK2/4/6. p27 is responsible for turning the G1 CDKs ON and OFF during periods of proliferation and quiescence, respectively, and this transition is mediated by a specific modification to p27 itself, by the tyrosine kinase BRK (Breast tumor Related Kinase). A naturally occurring ALTernatively spliced form of BRK, named ALT, can bind to p27, blocking BRK's association with and phosphorylation of p27. The binding of ALT to p27 locks both CDK4/6 and CDK2 into the OFF conformation, inhibiting activity of both kinases. p27's association with CDK2 also prevents p27's degradation. In in vitro kinase assays, inducible ALT expression in ER+ breast cancer cells, inhibited CDK4/6 and CDK2 activities simultaneously, resulting in durable growth arrest. As p27 associates preferentially with the G1 CDKs, the specificity of ALT for these kinases is achieved by p27 itself, thus avoiding off-target kinase interactions with the rest of the CDK kinome. We engineered IpY.20, a smaller, more stable variant of ALT, formulated within a liposome to increase its serum residence time and facilitate delivery into tumor cells. IpY.20 inhibits cell proliferation of HR+ and triple negative (TN) breast cancer, ovarian, uterine and NSCLC, preferentially over non-tumor cells, supporting its clinical utility. Unlike CDK4/6i and CDK2i which only cause cytostasis, IpY.20 arrests proliferation and induces cell death, demonstrating that p27 inhibition is a viable therapeutic approach to combat CDK4/6i-dependent drug resistance. In vivo, IpY.20 reduces tumor volume in palbociclib-resistant ER+ xenografts, TN xenografts and the MMTV-ErbB2 spontaneous breast cancer model. IpY.20 does not cause the adverse effects seen in the presence of CDK4/6i or CDK2i: IpY.20 does not cause neutropenia, and in combination with palbociclib, IpY.20 rescues the CDK4/6i-dependent decrease in neutrophils, suggesting better tolerability in patients. IpY.20 is detected in tumors within 15 min. of single dose I.V. administration and continues to be detectable for 24 h. IpY.20 is currently completing CMC process optimization, batch-to-batch consistency, and stability as it moves into the IND program. These findings underscore the significance of targeting CDK2, CDK4, and CDK6 simultaneously via p27 modulation as a potential therapy. Given the difficulties in inhibiting the CDK2/4/6 hub with small molecule CDKi (off-target kinase selectivity, adverse effects, lack of tumor cell killing), targeting p27 may provide advantages to the post-CDK4/6i setting. Citation Format: Grace Chen, Natalia Zisman, Krishna Allamneni, Stacy W Blain. Triple CDK2/4/6 inhibition via p27 modulation: A novel approach to targeting cell cycle dysregulation [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr B018.

Abstract 3057: CDK5 Modulates the Cell Cycle, Apoptosis and Paclitaxel Sensitivity in Human Ovarian Cancer Cells with Wild-Type P53 Function

Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells with Acquired Paclitaxel Resistance

The dispersion of radioactive phosphorus in the embryonated hen's egg.

Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells

PGAM1 Modulates Paclitaxel-Resistance in Ovarian Cancer Cells Through Controlling Pyruvic Acid Production in Glycolysis

Paclitaxel Resistance in Ovarian Cancers Relies on a PGAM1 Mediated Glycolytic Metabolism

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis

Abstract B058: Targeting mediator kinase CDK8/19 potentiates chemotherapeutic responses, reverses tumor growth, and prolongs survival from ovarian clear cell carcinoma

Reduced Expression of P53 and P21(Waf1/Cip1) Sensitizes Human Breast Cancer Cells to Paclitaxel and Its Combination with 5-Fluorouracil

Low programmed cell death 5 expression is a prognostic factor in ovarian cancer.

Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer

Abstract A057: Therapeutic efficacy of selective CDK7 inhibition in pancreatic cancer mediated by induction of R-loop formation, DNA replication stress and genomic instability

Abstract B018: Triple CDK2/4/6 inhibition via p27 modulation: A novel approach to targeting cell cycle dysregulation

Cytoplasmic SIRT1 promotes paclitaxel resistance in ovarian carcinoma through increased formation and survival of polyploid giant cancer cells

CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5

Cyclin Dependent Kinase 14 As a Paclitaxel-Resistant Marker Regulated by the TGF-β Signaling Pathway in Human Ovarian Cancer.

CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma

Abstract 2117: Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers